tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
David Dai

David Dai

SMBC Nikko
Wall Street Analyst
Ranked #6,465 out of 8,050 Analysts on TipRanks (#17,342 out of 21,576 overall experts)

Success Rate

43%
3 out of 7 Profitable Transactions

Average Return

-9.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied David Dai's ratings since 2022 and opened each position for the duration of 1 Year:
42.86% of your transactions would have been profitable with an average return of -9.3%

Stock Rating Distribution

8Ratings
87.50% Buy
12.50% Hold
0.00% Sell
Distribution of David Dai's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Nkarta, Inc.
(NKTX)
Rating Type:Buy
Dates:May 16, 2022 - Jan 01, 1970
Gain:27.90%
The most profitable rating made by David Dai

David Dai's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Jounce Therapeutics
Mar 15, 2022
Buy
Initiated
$17.00
(268.76% Upside)
0%
-30.40%
1
Inhibrx
Mar 15, 2022
Buy
Initiated
$40.00
(71.97% Upside)
100%
+17.20%
1
Adicet Bio
Mar 30, 2022
Buy
Initiated
$28.00
(107.25% Upside)
0%
-28.40%
1
Xencor
May 09, 2022
Buy
Reiterated
$54.00
(76.70% Upside)
50%
+8.20%
2
Nkarta
May 16, 2022
Buy
Reiterated
$40.00
(132.42% Upside)
100%
+27.90%
1
MacroGenics
Jul 18, 2022
Hold
Downgraded
$5.00
(10.38% Upside)
0%
-68.10%
2
List of latest recommendations made by David Dai. Click to expand and see David Dai's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More